VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

T. cruzi vaccine using Sendai virus vector expressing amastigote surface protein-2
Vaccine Information
  • Vaccine Name: T. cruzi vaccine using Sendai virus vector expressing amastigote surface protein-2
  • Target Pathogen: Trypanosoma cruzi
  • Target Disease: Chagas disease
  • Vaccine Ontology ID: VO_0001394
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: Parasite antigen amastigote surface protein-2 (ASP2) (Duan et al., 2009).
  • amastigote surface protein-2 gene engineering:
    • Type: Recombinant vector construction
    • Description:
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intranasally
Host Response

Mouse Response

  • Host Strain: C57BL/6
  • Vaccination Protocol: B6 mice were administrated intranasally with 5 × 10^6 CIU SeV-GFP or SeV-ASP2 (Duan et al., 2009).
  • Challenge Protocol: For challenge infections, mice were inoculated with 1000 blood-derived trypomastigotes at the base of the tail 2 weeks after immunization (Duan et al., 2009).
  • Efficacy: C57BL/6 mice immunized intranasally with rSeV/dF expressing ASP2 showed significantly suppressed parasitemia and could be protected from lethal T. cruzi challenge (Duan et al., 2009).
References
Duan et al., 2009: Duan X, Yonemitsu Y, Chou B, Yoshida K, Tanaka S, Hasegawa M, Tetsutani K, Ishida H, Himeno K, Hisaeda H. Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2. Vaccine. 2009; 27(44); 6154-6159. [PubMed: 19712768].